Explore the words cloud of the MARKinPATH project. It provides you a very rough idea of what is the project "MARKinPATH" about.
The following table provides information about the project.
Coordinator |
VENTER PHARMA S.L.
Organization address contact info |
Coordinator Country | Spain [ES] |
Project website | http://www.venterpharma.com |
Total cost | 71˙429 € |
EC max contribution | 50˙000 € (70%) |
Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
Code Call | H2020-SMEINST-1-2014 |
Funding Scheme | SME-1 |
Starting year | 2014 |
Duration (year-month-day) | from 2014-10-01 to 2015-02-28 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | VENTER PHARMA S.L. | ES (ALCOBENDAS) | coordinator | 50˙000.00 |
MARKinPATH global innovation project aims at undertake the clinical validation of Xylose, after ingestion of Gaxilose, as a Biomarker of intestinal diseases. Currently, the measurement of Xylose after ingestion of Gaxilose is used to evaluate hypolactasia in adults. MARKinPATH is focused to improve the hypolactasia diagnosis; broaden the pathologies to monitor and to extend his use to paediatrics population.
MARKinPATH will meet the demand of the EU on and innovation in healthcare, by enhancing diagnosis and management of intestinal pathologies. The resulting solution will also contribute to cost-effective and efficient health expenditure. Xylose-based, after ingestion of Gaxilose, biomarker improves technical features such as specificity and sensitivity with respect to the other tests available in regular clinical practice. Furthermore, alternative methods such as Hydrogen breath test (HBT) and the Lactose tolerance test (LTT) are invasive and have adverse effects that can be very annoying for the patient.
Venter Pharma is a highly innovative SME with more than 11 years focused on advanced research, development and commercialization of clinical solutions in this field. Venter Pharma has a relevant Intellectual Capital and an extensive background in these technologies.
MARKinPATH would suppose a massive-but-necessary growth and the consolidation of Venter Pharma in the pharmaceutical market.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MARKINPATH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "MARKINPATH" are provided by the European Opendata Portal: CORDIS opendata.
Reshaping undesired Inflammation in challenged Tissue Homeostasis by Next-Generation regulatory T cell (Treg) Approaches – from Advanced Technology Developments to First-in-Human Trials
Read More